Modular Medical Announces Licensing and Partnership Agreement With Nudge BG was announced by AccessWire.com, 19 December 2024.
Modular Medical, Inc., an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of “almost-pumpers” with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG.
“We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery (“AID”) to the marketplace,” said Lane Desborough, CEO of Nudge BG. “Nudge BG’s adaptive full closed-loop AID technology, unlike the present Hybrid Closed Loop products, complements Modular Medical’s easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor.”
“We believe most people living with insulin-requiring diabetes find it difficult or impossible to sustain the therapy effort which contemporary AID systems demand, including counting carbohydrates and calculating bolus delivery amounts, preventing them from reaping the benefits of the present technology. It has been the goal of Nudge BG to design an AID system that will truly make the diabetes management experience both effective and less burdensome for users. Our system will fully automate mealtime insulin delivery, freeing people with diabetes from the risk and difficulty of bolusing, while still achieving glycemic goals,” said Desborough.
Paul DiPerna, President and CTO of Modular Medical, stated “Our goal at Modular Medical is to bring the benefits of insulin pump technology to the approximately 80% of potential adopters who are not on pumps because they see current AID-enabled systems as too complex, too cumbersome, and too costly. The Nudge BG partnership is another step in our efforts to make the experience of diabetes management as low touch and simple as possible by reducing the amount of time, training, and effort a user will spend daily on managing insulin, while still providing the beneficial results of pumping as compared to multiple daily injections.”
Read more: Modular Medical Announces Licensing and Partnership Agreement With Nudge BG
Dexcom adds generative AI to over-the-counter CGMs by Elise Reuter for MedTechDive.com, 18 December 2024.
Dexcom has launched a generative AI feature for its over-the-counter glucose sensors. The feature will analyze patterns in users’ health data to provide more personalized tips, recommendations and education around diet, exercise and sleep, the company said in a press release.
Dexcom’s new capability comes as the Food and Drug Administration is exploring how to regulate generative AI in medical devices. Dexcom spokesperson Janika Kelly said the company evaluated the generative AI feature according to FDA guidance documents and it did not require a premarket submission. “While this is a new territory for the FDA, we are working with them to follow their framework for GenAI,” Kelly said. “The generative AI feature will add more personalized information to its weekly insights for users. It does not provide medical advice or recommendations. And we are also providing feedback to and seeking input from the FDA as we take steps to incorporate GenAI into our product” Kelly added.
The feature is based on Google Cloud’s Vertex AI development platform and its Gemini large language models. Dexcom Chief Operating Officer Jake Leach said in the announcement that the company plans to introduce additional generative AI-powered features over the next year “to help users contextualize their health information and make proactive, informed lifestyle decisions.”
Read more: Dexcom adds generative AI to over-the-counter CGMs
New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes by the University of Illinois Chicag, 25 November 2024.
A new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is available exclusively at UI Health in Chicago. Pancreatic islet cell therapy is a treatment approved by the FDA only for adults with type 1 diabetes who struggle to control their blood sugar levels due to frequent episodes of severe low blood sugar and hypoglycemia unawareness, a condition that occurs when patients can’t detect that their blood sugar is dropping. This new therapy, called Lantidra, is derived from a deceased donor pancreas. To regulate blood glucose, the drug is infused into the patient’s liver where insulin is produced. Lantidra requires a donor match determined by the United Network for Organ Sharing.
According to Dr. Enrico Benedetti, head of surgery at UI Health, most patients in the clinical trial no longer required insulin one year after their transplant. Before islet cell transplantation, the only treatment option for brittle type 1 diabetes was a pancreas transplant.
If the Lantidra therapy is successful, the islet cells lodge in the small blood vessels of the liver and begin producing insulin. Patients must take immunosuppressant drugs to prevent rejection of the islet cells. In some cases, patients require more than one infusion of donor islet cells to produce enough insulin. The success of the treatment varies from patient to patient.
Read more: New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes
Endocrinologist Deserts: A Critical Healthcare Gap for Millions in the U.S. by Tori Marsh for GoodRx.com, 17 December 2024.
A staggering two-thirds of U.S. counties don’t have any practicing endocrinologists. In these “endocrinologist deserts,” 50 million Americans struggle to get specialized care for conditions like diabetes, thyroid disorders and obesity.
Nearly 70% of counties don’t have an endocrinologist: The map below reveals the scope of endocrinologist deserts (2,168 counties and nearly 70% of all counties). The affected areas stretch from the Midwest to the South. In these regions, patients may face delayed care or diagnoses, difficulty managing chronic conditions, and/or more complications. Residents of endocrinologist deserts have significantly higher rates of obesity, diabetes, and related complications. They also have higher death rates from endocrine-related conditions. Without adequate access to care, millions of Americans are left to manage these complex conditions on their own, often with severe consequences.
Expanding access to endocrinology care is essential to bridge this healthcare gap. And doing so could save countless lives. This effort demands innovative solutions, such as:
-
- Creating telemedicine programs to overcome geographic barriers
- Providing incentives for specialists to practice in underserved areas
- Making broader investments in rural healthcare infrastructure
These solutions could potentially break the cycle of poor health outcomes in endocrinologist deserts. We could ensure all Americans have a fair chance at managing and overcoming preventable, life-altering diseases, especially in rural America.
Type 1 Diabetes Market Projected to Hit USD 24.36 Billion by 2031 according to Coherent Market Insights for BioSpace.com, 11 December 2024.
The global market of type 1 diabetes market is projected to be valued at USD 15.95 billion in 2024 and expected to reach USD 24.36 billion with a compound annual growth rate of 6.2% during this period. This information is according to the report of Coherent Market Insights Inc.
Increasing the patient pool across the globe will fuel the demand for Type 1 Diabetes globally. As per the International Diabetes Federation, in 2021, about 1.1 million children and adolescents suffered from type 1 diabetes globally. It is predicted that about 100,000 new cases are expected to be reported every year.
Another key driver is the increasing adoption of sedentary lifestyle which is leading to a rise in risk of type 1 diabetes. Advancements in drugs & treatment technologies coupled with growing healthcare expenditure is also fueling the market growth.
Read more: Type 1 Diabetes Market Projected to Hit USD 24.36 Billion by 2031
